Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancerEya Wolfson, Ronit Pinkas‐Kramarski|Cell Death and Disease|2018Cited by 43
Nucleolin-binding by ErbB2 enhances tumorigenicity of ErbB2-positive breast cancerEya Wolfson, Ronit Pinkas‐Kramarski|Oncotarget|2016Cited by 38
Nucleolin inhibitor GroA triggers reduction in epidermal growth factor receptor activation: Pharmacological implication for glial scarring after spinal cord injuryYona Goldshmit, Ronit Pinkas‐Kramarski|Journal of Neurochemistry|2016Cited by 10
Continuous treatment with FTS confers resistance to apoptosis and affects autophagyEran Schmukler, Ronit Pinkas‐Kramarski|PLoS ONE|2017Cited by 4